Heart Metabolics

Heart Metabolics Limited is a London, UK-based drug developer for the treatment of heart failure in patients with hypertrophic cardiomyopathy. Led by Dr. Peter Milner, CEO, Heart Metabolics Limited is developing new therapies targeting cardiac metabolic diseases. Its lead candidate, perhexiline, has completed Phase II clinical trials for the treatment of hypertrophic cardiomyopathy (HCM). The company has received orphan drug designation from the FDA for the use of perhexiline as a first-line treatment for moderate to severe heart failure caused by HCM.